Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Y Miao, D Dobre, H J Lambers Heerspink, B M Brenner, M E Cooper, Hans-Henrik Dyring Parving, S Shahinfar, D Grobbee, D de Zeeuw

    93 Citationer (Scopus)

    Abstract

    To assess the effect of an angiotensin receptor blocker (ARB) on serum potassium and the effect of a serum potassium change on renal outcomes in patients with type 2 diabetes and nephropathy.
    OriginalsprogEngelsk
    TidsskriftDiabetologia
    Vol/bind54
    Udgave nummer1
    Sider (fra-til)44-50
    Antal sider7
    ISSN0012-186X
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial'. Sammen danner de et unikt fingeraftryk.

    Citationsformater